Navigation Links
Protein is potential new treatment target for adult pulmonary hypertension
Date:10/17/2011

AUGUSTA, Ga. A protein critical to development appears to have a grave impact on lungs exposed to smoking and air pollution, researchers report.

Blocking that protein, called calpain, in the lungs may prove an effective way to avoid narrow, scarred blood vessels and pulmonary hypertension, said Dr. Yunchao Su, pharmacologist at Georgia Health Sciences University.

"Calpain enables the bad behavior that occurs in pulmonary hypertension," said Su, corresponding author of the study published in the Journal of Clinical Investigation.

Pulmonary hypertension is an often progressive and deadly condition in which tiny blood vessels that permeate the lungs narrow, raising blood pressure and eventually enlarging the pumping chamber of the heart as it struggles to get blood inside the lungs.

Babies with heart defects can have it, but in adults it can result from chronic obstructive lung disease, or COPD, primarily caused by smoking (emphysema is the most common form of COPD) or air pollutants, including second-hand smoke. Inflamed and poorly oxygenated lungs start producing growth factors and other measures to constrict blood vessels in an effort to restore balance between blood flow and oxygen levels. This works in the short term, Su said, but a chronic stimulus such as smoking can make, ongoing constriction debilitating or deadly. Treatment improves symptoms such as shortness of breath, but the only cure is a heart-lung transplant.

Researchers found calpain gets activated by growth factors released by stressed lung tissue then multiplies the vascular remodeling by cleaving TGFbeta, another growth factor typically inactive in the lungs. Cleaving TGFbeta releases a strong, active form that increases cell proliferation and collagen production. A similar process helps heal a cut on the hand, but inside the blood vessel it's counterproductive, Su said.

Additionally, in animal models of pulmonary hypertension as well as lungs removed from patients getting a transplant, the researchers found elevated levels of calpain. When they blocked its action by giving an inhibitor or removing its gene, TGFbeta was not activated and vascular remodeling and scarring as well as the heart damage were prevented. "The pulmonary process was close to normal," Su said.

Next steps include seeing whether the calpain inhibitor can stop cell proliferation and collagen synthesis in lung cells removed during a biopsy. Toxicology studies also will be needed before looking toward clinical trials, Su said.

He noted that a calpain inhibitor is likely not feasible for children because of the protein's importance in development. He envisions an inhalable version of the inhibitor to minimize any side effects in adults.

Su's earlier studies helped define calpain's role in cell proliferation when he found that lung cells in culture healed just fine after being cut until he added the calpain inhibitor. The work was published in 2006 in the The FASEB Journal. Su suspected then that calpain also had a role in pulmonary hypertension.


'/>"/>

Contact: Toni Baker
tbaker@georgiahealth.edu
706-721-4421
Georgia Health Sciences University
Source:Eurekalert  

Related biology news :

1. Photonic crystal biosensors detect protein-DNA interactions
2. Penn biophysicists create new model for protein-cholesterol interactions in brain and muscle tissue
3. Dont forget the vitamin A when working with its carrier protein
4. Saliva proteins could help detection of oral cancer
5. The structure of the Mre11 protein bound to DNA
6. New lab manual focuses on essential methods for purifying and characterizing proteins
7. Proteins in sperm unlock understanding of male infertility says new study
8. Response to immune protein determines pathology of multiple sclerosis
9. Columbia to award 2008 Horwitz Prize to Arthur Horwich & Ulrich Hartl for cellular protein folding
10. Human protein atlas will help pinpoint disease
11. How neuronal activity leads to Alzheimers protein cleavage
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Protein is potential new treatment target for adult pulmonary hypertension
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... -- Despite the volatility that continues to envelop ... pre-market research on ActiveWallSt.com directs the investor community,s focus on ... RDUS ), Cerus Corp. (NASDAQ: CERS ), Arrowhead ... Therapeutics Inc. (NASDAQ: FPRX ). Register with us ... http://www.activewallst.com/ On Wednesday, shares in ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s ... in San Francisco. Located at booth number 7301, representatives from the Thai Government, ... discuss the Thai biotechnology and life sciences sector. , Deputy Secretary General ...
(Date:5/25/2016)... ... , ... WEDI, the nation’s leading authority on the use of health IT ... been named by the WEDI Board of Directors as WEDI’s president and CEO. Stellar ... more than 35 years of experience in healthcare, association management and organizational leadership, Stellar ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated wealth management ... The Future of San Diego Life Science event at the Estancia La Jolla Resort ... the event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and ...
Breaking Biology Technology: